Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03199274 · ClinicalTrials.gov registry record · Phase 2
Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
A Phase 2 study of Hepatocellular Carcinoma, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT03199274 is a Phase 2 study of Hepatocellular Carcinoma that has completed, run by Thomas Jefferson University. The registered enrollment target is 104 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03199274, a Phase 2 study of Hepatocellular Carcinoma, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well perflutren protein-type A microspheres and contrast-enhanced ultrasound work in improving response to radioembolization therapy in patients with liver cancer. Ultrasound contrast agents, such as perflutren protein-type A microspheres, use gas microbubbles to improve image quality. Using contrast-enhanced ultrasound imaging will "pop" these microbubbles and cause tumors to become more sensitive to radiation therapies.
Conditions Studied
Interventions
- PROCEDURE Yttrium-90 Microsphere Radioembolization
- DRUG Perflutren Protein-Type A Microspheres
- PROCEDURE Dynamic Contrast-Enhanced Ultrasound Imaging
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2025-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03199274
The ClinicalTrials.gov registry entry for NCT03199274 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (60% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Yttrium-90 Microsphere Radioembolization is the first listed.
NCT03199274 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03199274 about?
NCT03199274 is a clinical study titled "Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer". This phase II trial studies how well perflutren protein-type A microspheres and contrast-enhanced ultrasound work in improving response to radioembolization therapy in patients with liver cancer. Ultrasound contrast agents, such as perflutren protein-type A microspheres, use gas microbubbles to impr...
What is the current status of trial NCT03199274?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2017-07-01. Estimated completion is 2025-01-23.
What conditions does trial NCT03199274 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT03199274?
The interventions under investigation include: Yttrium-90 Microsphere Radioembolization (PROCEDURE), Perflutren Protein-Type A Microspheres (DRUG), Dynamic Contrast-Enhanced Ultrasound Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT03199274?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03199274 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.